Ross Cummings

Biotech vs Medtech: Differences in Mapping an IP Portfolio

This article was originally published on Biotech and Money as a two-part series. Read part one here. IP portfolio management is often overlooked, but is extremely important if the goal is to protect products or services in the most cost-efficient way possible. However, the process of mapping an IP portfolio to...

Read more

Biotech vs Medtech: Divergence in Intellectual Property Strategy

The landscape of innovation and investment in the healthcare sector has changed dramatically with the digital revolution and the rise of medtech – the physical devices used in healthcare – ranging from drug delivery devices to diagnostic kits and software for the interpretation of health and wellbeing data. Investors in...

Read more

Loss of priority leads to revocation of key CRISPR patent at European Patent Office

In a previous article, we reported on the preliminary opinion of the Opposition Division issued during the opposition to the Broad Institute’s European CRISPR patent EP2771468. Yesterday, the oral hearing before the opposition division at the European Patent Office (EPO) deciding this matter was concluded with complete revocation of the...

Read more

Has the European Patent Office over-turned the Enlarged Board of Appeal decisions on patentability of products of essentially biological processes?

The European Patent Convention (EPC) excludes from patentability inventions consisting of plant or animal varieties or essentially biological processes for the production of plants or animals (this does not apply to microbiological processes or the products thereof).  An “essentially biological process” is defined in the EPC as consisting entirely of...

Read more